Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

15.80
-0.8100-4.88%
Post-market: 15.800.00000.00%17:24 EDT
Volume:198.17K
Turnover:3.21M
Market Cap:406.46M
PE:-0.68
High:16.75
Open:16.58
Low:15.80
Close:16.61
Loading ...

Promising Developments and Strategic Expansion Bolster Buy Rating for Cartesian Therapeutics

TIPRANKS
·
29 Jan

Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design

MT Newswires Live
·
27 Jan

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Dow Jones
·
27 Jan

Positive Buy Rating for Cartesian Therapeutics Amid Encouraging Developments in Descartes-08 Trials

TIPRANKS
·
27 Jan

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis

THOMSON REUTERS
·
27 Jan

Promising Developments and Strategic Milestones Drive Buy Rating for Cartesian Therapeutics

TIPRANKS
·
15 Jan

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Dow Jones
·
14 Jan

Buy Rating for Cartesian Therapeutics Driven by Promising Clinical Pipeline and Financial Stability

TIPRANKS
·
14 Jan

BRIEF-Cartesian Therapeutics Highlights Progress And 2025 Strategic Priorities

Reuters
·
13 Jan

Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of Mrna Cell Therapies for Autoimmune Diseases

THOMSON REUTERS
·
13 Jan

Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 to Commence in 1H25

THOMSON REUTERS
·
13 Jan

Cartesian Therapeutics Inc - Cash Resources Expected to Support Operations Into Mid-2027

THOMSON REUTERS
·
13 Jan

Cartesian Therapeutics Inc - Phase 2 Sle Trial of Descartes-08 Ongoing, Data Readout Expected 2H25

THOMSON REUTERS
·
13 Jan

Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?

Zacks
·
13 Jan

Cartesian Therapeutics announces employment inducement grants

TIPRANKS
·
07 Jan

Cartesian Therapeutics (RNAC) Has a New Rating from BTIG

TIPRANKS
·
31 Dec 2024